Cambridge, UK and Indianapolis, US – 7 May 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that its annual general meeting of shareholders (“AGM”) will be held at 11.00 am BST on Monday, 3 June 2019 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, UK.
The formal notice convening the AGM (including agenda, information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting) together with the Form of Proxy, and the Company’s Annual Report and Accounts for the year ended 31 December 2018, will be posted to shareholders today and are available from today on the Company’s website www.acaciapharma.com in the Investors/Shareholder Meetings section and the Investors/Financial Reports section, respectively.
Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group’s lead project, BARHEMSYS® for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com